S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Warning: Biden’s Big Blackout is Coming (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Warning: Biden’s Big Blackout is Coming (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Warning: Biden’s Big Blackout is Coming (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Warning: Biden’s Big Blackout is Coming (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:BMRA

Biomerica - BMRA Stock Forecast, Price & News

$2.87
0.00 (0.00%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.86
$2.88
50-Day Range
$2.80
$3.88
52-Week Range
$2.56
$5.25
Volume
11,259 shs
Average Volume
29,483 shs
Market Capitalization
$38.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BMRA stock logo

About Biomerica (NASDAQ:BMRA) Stock

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.

Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

BMRA Stock News Headlines

A step-by-step guide to Investing Outside the Stock Market.
Experts from BofA to Blackrock agree: the 60-40 asset allocation model is outdated. With equity forecasts at historic lows, top portfolio managers are turning to alternative assets like fine art to potentially enhance returns. Fine art is a $1.7 trillion-dollar asset class that's outpaced the S&P 500 by more than 2x in the last 25 years. With Masterworks, it's easy for anyone to invest in art. Get started today with a special link. **See important disclosures pixel
3 Secrets To Consistent Trading Success
Don't get caught in the trap of standing on the sidelines of intermarket correlation. The truth is that it’s impossible for you (or any human) to visualize and calculate complicated intermarket causations. Learn with A.I. which global markets have the most influence on a target market. Save a Seat for This Free Live Training. pixel
See More Headlines
Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

BMRA Company Calendar

Last Earnings
1/13/2022
Today
2/09/2023
Next Earnings (Estimated)
4/13/2023
Fiscal Year End
5/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BMRA
Employees
66
Year Founded
1971

Profitability

Net Income
$-4,530,000.00
Pretax Margin
-34.48%

Debt

Sales & Book Value

Annual Sales
$18.87 million
Book Value
$0.65 per share

Miscellaneous

Free Float
11,363,000
Market Cap
$38.69 million
Optionable
Not Optionable
Beta
-0.57

Social Links


Key Executives

  • Zackary S. Irani
    Chairman & Chief Executive Officer
  • Steve Sloan
    Chief Financial Officer & Treasurer
  • Robert Carlson
    Chief Commercial Officer













BMRA Stock - Frequently Asked Questions

Should I buy or sell Biomerica stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BMRA shares.
View BMRA analyst ratings
or view top-rated stocks.

How have BMRA shares performed in 2023?

Biomerica's stock was trading at $3.35 on January 1st, 2023. Since then, BMRA stock has decreased by 14.3% and is now trading at $2.87.
View the best growth stocks for 2023 here
.

Are investors shorting Biomerica?

Biomerica saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 397,200 shares, a decline of 8.1% from the December 31st total of 432,300 shares. Based on an average trading volume of 28,000 shares, the short-interest ratio is presently 14.2 days. Approximately 3.5% of the shares of the stock are sold short.
View Biomerica's Short Interest
.

When is Biomerica's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 13th 2023.
View our BMRA earnings forecast
.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) posted its earnings results on Thursday, January, 13th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. The company had revenue of $4.65 million for the quarter. Biomerica had a negative net margin of 34.58% and a negative trailing twelve-month return on equity of 66.11%.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

Who are Biomerica's major shareholders?

Biomerica's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.47%), Hollencrest Capital Management (0.37%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allen Barbieri, Catherine Coste, Mark A Sirgo and Zackary S Irani.
View institutional ownership trends
.

How do I buy shares of Biomerica?

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $2.87.

How much money does Biomerica make?

Biomerica (NASDAQ:BMRA) has a market capitalization of $38.69 million and generates $18.87 million in revenue each year. The company earns $-4,530,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The official website for the company is www.biomerica.com. The company can be reached via phone at (949) 645-2111, via email at jnesbett@institutionalms.com, or via fax at 949-553-1231.

This page (NASDAQ:BMRA) was last updated on 2/9/2023 by MarketBeat.com Staff